跳转至内容
Merck
CN

238811

Sigma-Aldrich

Cdk9 Inhibitor II

The Cdk9 Inhibitor II, also referenced under CAS 140651-18-9, controls the biological activity of Cdk9. This small molecule/inhibitor is primarily used for Phosphorylation & Dephosphorylation applications.

别名:

Cdk9 Inhibitor II, 4-(3,5-Diamino-1H-pyrazol-4-ylazo)-phenol

登录查看公司和协议定价

选择尺寸


关于此项目

经验公式(希尔记法):
C9H10N6O
化学文摘社编号:
分子量:
218.22
MDL编号:
UNSPSC代码:
12352200
NACRES:
NA.77
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

质量水平

方案

≥95% (HPLC)

表单

solid

制造商/商品名称

Calbiochem®

储存条件

OK to freeze
protect from light

颜色

orange

溶解性

DMSO: 10 mg/mL
ethanol: 5 mg/mL

运输

ambient

储存温度

2-8°C

SMILES字符串

[nH]1nc(c(c1N)N=Nc2ccc(cc2)O)N

InChI

1S/C9H10N6O/c10-8-7(9(11)15-14-8)13-12-5-1-3-6(16)4-2-5/h1-4,16H,(H5,10,11,14,15)

InChI key

AYZRKFOEZQBUEA-UHFFFAOYSA-N

一般描述

A cell-permeable azo-pyrazole compound that acts as a potent, ATP-competitive, and Cdk9-selective inhibitor (IC50 = 350 nM, using Cdk9/T1). It inhibits Cdk1/B, Cdk2/E, Cdk2/A, Cdk4/D1, Cdk7/H, and p70S6K only at much higher concentrations (IC50 = 44, 20, 69, 13.5, 26, and 10 µM, respectively) and shows little or no activity against eight other commonly studied kinases even at concentrations as high as 10 µM. Shown to exhibit antiproliferative activity in human tumor cell lines.

生化/生理作用

Cell permeable: yes
Primary Target
Cdk9
Product competes with ATP.
Reversible: no
Target IC50: 350 nM, using Cdk9/T1

包装

Packaged under inert gas

其他说明

Krystof, V., et al. 2006. J. Med. Chem.49, 6500.

法律信息

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

免责声明

Toxicity: Irritant (B)

储存分类代码

11 - Combustible Solids

WGK

WGK 2

闪点(°F)

Not applicable

闪点(°C)

Not applicable


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

XinTao Gao et al.
Molecular oncology, 15(7), 1901-1920 (2021-05-02)
Androgen receptor (AR) is the principal molecule in prostate cancer (PCa) etiology and therapy. AR re-activation still remains a major challenge during treatment of castration-resistant prostate cancer (CRPC) tumors that relapse after castration therapies. Recent reports have indicated the enrichment

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持